Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ReNeuron Group PLC

+ Add to Watchlist


3.625 GBp 0.0000.00%

As of 11:35:28 ET on 03/30/2015.

Snapshot for ReNeuron Group PLC (RENE)

Open: 3.625 Day's Range: 3.625 - 3.625 Volume: 1,185,303
Previous Close: 3.625 52wk Range: 2.750 - 4.390 1-Yr Rtn: +13.28%

Stock Chart for RENE

No chart data available.
  • RENE:LN 3.625
  • 1D
  • 1M
  • 1Y
Interactive RENE Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RENE

Current P/E Ratio (ttm) -
Estimated P/E(03/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.0040
Est. EPS (GBP) (03/2015) -0.0050
Est. PEG Ratio -
Market Cap (M GBP) 64.85
Shares Outstanding (M) 1,788.83
30 Day Average Volume 1,230,265
Price/Book (mrq) 2.5533
Price/Sale (ttm) 2,813.1448
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 06/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RENE

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for RENE

ReNeuron Group PLC is a United Kingdom-based adult stem cell research and development company. The Company is applying its novel stem cell platform technologies in the development of stem cell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron Group has also leveraged its stem cell technologies into the non-therapeutic areas such as drug discovery.

Terje Olav HelleboeChief Executive OfficerMichael Elliott HuntChief Financial Officer
John SindenChief Scientific Ofcr/Co-FounderRichard MoulsonSecretary
More Company Profile & Key Executives for RENE

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil